The industry is at an interesting inflection point

Aligned interest and motivations in the changing centers of care will determine the future of the products and platforms in the medtech / healthtech industry.

It will drive venture investment, which fuels innovation.

Rewards drive behaviors.

The changing centers of care are likely to be one of the toe-holds of opportunity for emerging technologies that otherwise would be relegated to selling their products or services into hospitals.
Health at Home (HaH) is one of those locations and ASC’s are another.

HaH will offer a tremendous opportunity in the reduction of costs to the healthcare system, especially in the case of management of chronic disease states, which constitute nearly 80% of the 18% of the U.S.’s GDP.

When CMS changed reimbursement for HaH in November of 2020, it opened the possibility of the emerging market of lower cost and higher fidelity sensor technologies.

While that is promising, it will be curious to see how the American Hospital Association (AHA), who is the country’s fifth largest lobbying groups for the government, will navigate this attempted transition.
It is important to note that more than a third of the $4+trillion in health expenditures in 2021 went to hospitals.

As is the case with most of the digital insight technologies emerging, as well as the home health solutions, the questions remains…

“Who is going to pay for it and how are the Providers and/or the Manufacturers going to be paid?”

Changes in reimbursement and an alignment of interests in our healthcare system with the intention to reduce costs, expand access, and improve outcomes is a critical pivot point around the success of emerging technologies and changing centers of care.

The industry is at an interesting inflection point.